ClinicalTrials.gg
CompletedNCT00637559Updated Jan 25, 2011

Barrett's Esophagus - 315 - 3 Way Cross-Over

A Phase 4 interventional study of Esomeprazole Magnesium in Barrett's Esophagus, sponsored by AstraZeneca. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-25.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study looks the intragastric and intraesophageal pH in patients with documented Barrett's esophagus whilst taking esomeprazole 40mg twice daily, esomeprazole 40mg three times daily, esomeprazole 20 mg three times daily.

02

Conditions studied

  • Barrett's Esophagus

Browse trials for

Keywords

  • Nexium
  • Barrett's esophagus
03

In context

Barrett Esophagus

312 studies on the registry are indexed under Barrett Esophagus; 60 are open to participants now.

This study's planned enrollment of 50 is below the median of 62 across 187 interventional studies indexed under Barrett Esophagus.

Browse Barrett Esophagus studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have a previously established, -proven diagnosis of Barrett's esophagus with segment length greater than 3cm, with no dysplasia or adenocarcinoma within the previous 12 months

Exclusion criteria

Exclusion Criteria:

  • A history of esophageal, gastric, or duodenal surgery, including anti-reflux surgery or endoscopic anti-reflux procedures, except for simple closure of a gastric or duodenal ulcer.
  • History of various gastrointestinal diseases - please see investigator for full list.
  • Evidence of any malignant disease in the last 5 years, except minor superficial skin disease.
  • Unstable diabetes mellitus. Stable on a controlled diet, oral agents or insulin are acceptable.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    1

    40mg twice daily

    Drug: Esomeprazole Magnesium

  • Experimental
    2

    40mg three times daily

    Drug: Esomeprazole Magnesium

  • Experimental
    3

    20mg three times daily

    Drug: Esomeprazole Magnesium

Interventions

06

What researchers measure

Primary outcomes

  1. To compare the total percent time during the 24-hour monitoring period that gastric pH is above 4.0 at steady state in patients when taking: esomeprazole 40mg twice daily, esomeprazole 40mg three times daily, esomeprazole 20 mg three times daily.

    Time frame: pH measured on Day 5

Secondary outcomes

  1. Compare total percent time distal esophageal pH is above 4.0 at steady state for each treatment period.

    Time frame: pH measured

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2002, a primary completion of Apr 2003 and a completion of Apr 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2008
First posted
Mar 18, 2008
Start
Mar 2002
Primary completionActual
Apr 2003
CompletionActual
Apr 2003
Last update
Jan 25, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00637559
Lead sponsor
AstraZeneca
First posted
Mar 18, 2008
Start date
Mar 2002
Primary completion
Apr 2003
Completion
Apr 2003
Last update
Jan 25, 2011

Study contacts

Paula Fernstrom
study director · Nexium Global Product Director, AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion